Thermogenesis: Volume, Stock Jump in Late Trading

Photo of Douglas A. McIntyre
By Douglas A. McIntyre Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

by H.S. Ayoub
BioHealth Investor.com

Shares of Thermogenesis (KOOL) jumped both in price and volume during the last hour of trading on Wednesday. The stock ended regular hours trading at $3.13, up more than 16%, but after-hours trading gave back almost 10%.

What’s going on? For one, the stock seems over sold. Thermogenesis announced lower than expected numbers in its second quarter financial report due to an unexpected manufacturing problem, which created a backlog of orders for disposable bags used with the AutoXpress system. The company could not deliver on GE Healthcare’s (GE) orders. But the problem seems to have been fixed, according to the company, and orders should be filled quick enough to reflect on the third quarter report.

The recent sell-off in the markets have also dampened investor optimism, as Thermogenesis stock has crashed from the $4-$5 price range all the way down to around $2.60 just recently.

The fact that more than 50% of outstanding shares were held by institutional investors also contributed to the sell-off, after some firms had a change of heart following the last quarterly report.

Things could turn around just as fast however. On Monday, the company announced it has received three key patents for both its cord blood stem cell storage system, AutoXpress, and its surgical wound care unit, CryoSeal System.

Early on Wednesday, the stock recieved a buy recommendation from Maxim Group medical technology analyst Michael Tu with a price target of $5, more than 66% above the current price level. While that price target might seem a little too optimistic, consider the fact that Thermogenesis was hovering around $5 prior to their last quarterly report, only three months ago! The manufacturing problem has been fixed, so that large drop cannot be justified based on that issue alone.

Thermogenesis has historically been a relatively volatile stock, with a market cap of less than $200 million, and a large percentage of shares held by institutional investors, which tend to move in herds. If other firms follow Maxim’s lead, the stock could easily bounce back to the $5 range, especially if the next quarterly report reflects the updated manufacturing issue. This is with a continued market downturn not withstanding of course!

The late surge in trading on Wednesday could mean a couple of things; either the company is set to release great news on Thursday, or a large investor has decided to follow on Mr.Tu’s recommendation and buy a ‘few’ shares.

Whatever the reason may be, research analysts usually utilize good timing when releasing their recommendations. So the next few days could prove very interesting for Thermogenesis investors.

http://www.biohealthinvestor.com/

Photo of Douglas A. McIntyre
About the Author Douglas A. McIntyre →

Douglas A. McIntyre is the co-founder, chief executive officer and editor in chief of 24/7 Wall St. and 24/7 Tempo. He has held these jobs since 2006.

McIntyre has written thousands of articles for 24/7 Wall St. He is an expert on corporate finance, the automotive industry, media companies and international finance. He has edited articles on national demographics, sports, personal income and travel.

His work has been quoted or mentioned in The New York Times, The Wall Street Journal, Los Angeles Times, The Washington Post, NBC News, Time, The New Yorker, HuffPost USA Today, Business Insider, Yahoo, AOL, MarketWatch, The Atlantic, Bloomberg, New York Post, Chicago Tribune, Forbes, The Guardian and many other major publications. McIntyre has been a guest on CNBC, the BBC and television and radio stations across the country.

A magna cum laude graduate of Harvard College, McIntyre also was president of The Harvard Advocate. Founded in 1866, the Advocate is the oldest college publication in the United States.

TheStreet.com, Comps.com and Edgar Online are some of the public companies for which McIntyre served on the board of directors. He was a Vicinity Corporation board member when the company was sold to Microsoft in 2002. He served on the audit committees of some of these companies.

McIntyre has been the CEO of FutureSource, a provider of trading terminals and news to commodities and futures traders. He was president of Switchboard, the online phone directory company. He served as chairman and CEO of On2 Technologies, the video compression company that provided video compression software for Adobe’s Flash. Google bought On2 in 2009.

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.

Continue Reading

Top Gaining Stocks

CBOE Vol: 1,568,143
PSKY Vol: 12,285,993
STX Vol: 7,378,346
ORCL Vol: 26,317,675
DDOG Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ Vol: 4,367,433
CLX Vol: 13,260,523
SYK Vol: 4,519,455
MHK Vol: 1,859,865
AMGN Vol: 3,818,618